Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
281 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03958500 | The Problem of Colorectal Anastomosis Safety(ANSCRS) | completed | N/A | 60 | Vilnius UniversityOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT05378919 | Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer(RECTUM2015) | recruiting | Phase 2 | 250 | Lithuanian University of Health SciencesOTHER | 1 | May 18, 2022 |
| NCT02999633 | Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia(ISLAY) | terminated | Phase 2 | 14 | SanofiINDUSTRY | 7 | Mar 21, 2022 | clinicaltrials |
| NCT01813370 | A Registry for Patients Treated on the Clinical Trial TAX 3503 | completed | — | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Mar 8, 2022 | clinicaltrials |
| NCT01606566 | A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer. | terminated | Phase 2 | 26 | PCI Biotech ASINDUSTRY | 6 | Feb 18, 2022 | clinicaltrials |
| NCT03130790 | Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | completed | Phase 2 / Phase 3 | 52 | ASLAN PharmaceuticalsOTHER | 8 | Feb 15, 2022 | clinicaltrials |
| NCT04871165 | Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals | unknown | — | 3,270 | Vilnius UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT04810208 | Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours | terminated | Phase 1 | 6 | Lidds ABINDUSTRY | 3 | Dec 30, 2021 | clinicaltrials |
| NCT02630654 | Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs(EXPLAIN) | completed | — | 404 | IpsenINDUSTRY | 7 | Dec 7, 2021 | clinicaltrials |
| NCT02366143 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(IMpower150) | completed | Phase 3 | 1,202 | Hoffmann-La RocheINDUSTRY | 26 | Sep 23, 2021 | clinicaltrials |
| NCT00553358 | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study(Neo ALTTO) | completed | Phase 3 | 455 | Novartis PharmaceuticalsINDUSTRY | 24 | Sep 21, 2021 | clinicaltrials |
| NCT02808247 | Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma(ANITA) | terminated | Phase 2 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 20, 2021 | clinicaltrials |
| NCT02100696 | A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors(HICKORY) | completed | Phase 3 | 609 | Hoffmann-La RocheINDUSTRY | 24 | Aug 13, 2021 | clinicaltrials |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)(MERU) | terminated | Phase 3 | 748 | AbbVieINDUSTRY | 41 | Jul 29, 2021 | clinicaltrials |
| NCT02171429 | A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors(HIBISCUS II) | completed | Phase 3 | 358 | Hoffmann-La RocheINDUSTRY | 19 | Jul 23, 2021 | clinicaltrials |
| NCT00914628 | Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia(TK008) | terminated | Phase 3 | 92 | AGC Biologics S.p.A.INDUSTRY | 10 | Jun 22, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer(ExteNET) | completed | Phase 3 | 2,840 | Puma Biotechnology, Inc.INDUSTRY | 40 | Jun 11, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT02111577 | Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer(VIABLE) | completed | Phase 3 | 1,182 | SOTIO a.s.INDUSTRY | 22 | Apr 6, 2021 | clinicaltrials |
| NCT03070951 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 2) | completed | Phase 3 | 511 | ObsEva SAINDUSTRY | 9 | Mar 5, 2021 | clinicaltrials |
| NCT03348527 | A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer | completed | Phase 2 | 61 | Lidds ABINDUSTRY | 3 | Dec 21, 2020 | clinicaltrials |
| NCT02788214 | Helicobacter Pylori Genome Project (HpGP) | terminated | — | 1,000 | National Cancer Institute (NCI)NIH | 53 | Dec 19, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT01572038 | A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer(PERUSE) | completed | Phase 3 | 1,436 | Hoffmann-La RocheINDUSTRY | 39 | Sep 25, 2020 | clinicaltrials |
| NCT02671422 | LUME BioNIS: a Biomarker Study in Patients With NSCLC | completed | — | 260 | Boehringer IngelheimINDUSTRY | 13 | Sep 24, 2020 | clinicaltrials |
| NCT04427215 | Complementary and Alternative Medicine on Mental Health in Breast Cancer Patients | unknown | Phase 1 | 250 | Klaipėda UniversityOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03261999 | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer | completed | Phase 3 | 144 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 5 | May 4, 2020 | clinicaltrials |
| NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | completed | Phase 2 | 60 | Grifols Therapeutics LLCINDUSTRY | 10 | Mar 30, 2020 | clinicaltrials |
| NCT01212991 | A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer(PREVAIL) | completed | Phase 3 | 1,717 | PfizerINDUSTRY | 22 | Mar 17, 2020 | clinicaltrials |
| NCT00477282 | Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | completed | Phase 3 | 509 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 5 | Mar 12, 2020 | clinicaltrials |
| NCT00250276 | Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. | completed | Phase 3 | 798 | GlaxoSmithKlineINDUSTRY | 3 | Jan 2, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 | clinicaltrials |
| NCT03418428 | Intestinal Microbiome After Gastrectomy(DiGMA) | completed | — | 34 | Vilnius UniversityOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01576588 | Rituximab in Pretreated Elderly or Unfit B-CLL Patients | completed | Phase 2 | 25 | Prof. Dr. Med. Laimonas GriskeviciusOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT04030546 | Ivabradine to Prevent Anthracycline-induced Cardiotoxicity | unknown | Phase 3 | 128 | Vilnius UniversityOTHER | 1 | Dec 18, 2019 | clinicaltrials |
| NCT00415246 | Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer | terminated | Phase 3 | 100 | IpsenINDUSTRY | 8 | Nov 22, 2019 | clinicaltrials |
| NCT00057616 | Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma. | completed | Phase 3 | 274 | CelgeneINDUSTRY | 9 | Nov 8, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT01419717 | Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer | completed | Phase 3 | 129 | AmgenINDUSTRY | 19 | Sep 24, 2019 | clinicaltrials |
| NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma(RAINBOW) | completed | Phase 3 | 665 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 18, 2019 | clinicaltrials |
| NCT00191126 | Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC | completed | Phase 3 | 263 | Eli Lilly and CompanyINDUSTRY | 15 | Sep 12, 2019 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | completed | Phase 3 | 508 | Boehringer IngelheimINDUSTRY | 38 | Jul 18, 2019 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials